U.S. Tech Hardware Stock News

Digital Turbine, Inc. recently appointed Ben John, a veteran ad-tech and AI leader formerly at Microsoft and Xandr, as Chief Technology Officer to oversee global engineering, product architecture, data-centric scaling, and AI-driven development. This move comes alongside strong year-over-year revenue and EBITDA growth linked to international expansion and AI integration, highlighting management’s focus on turning technical capabilities into operational efficiency and business outcomes. We’ll...

Hims & Hers Health (HIMS) has capped FY 2025 with fourth quarter revenue of US$617.8 million and basic EPS of US$0.09, rounding out a year in which its trailing twelve month revenue reached about US$2.3 billion and basic EPS came in at roughly US$0.57. Over recent periods the company has seen revenue move from US$481.1 million in Q4 2024 to US$617.8 million in Q4 2025, while quarterly basic EPS shifted from US$0.12 a year ago to US$0.09 most recently. This has set up a results season where...

Ally Financial (NYSE:ALLY) approved a new $2 billion open-ended share repurchase program. The buyback plan follows a recent refresh of the company’s priorities and capital approach. The program adds a new capital return lever alongside existing efforts to refine the business mix. Ally Financial enters this move with its shares at $40.51 and a mixed performance profile, including a 14.7% gain over the past year and a 49.7% return over three years. Returns over the past month and year to date...

If you are wondering whether DuPont de Nemours shares still offer value at around US$51.07, it helps to step back and look at what the current price might be implying about the business. The stock has returned 0.4% over the last 7 days, 15.7% over the past month, 25.0% year to date and 52.3% over the past year, with longer term returns of 76.8% over 3 years and 83.4% over 5 years. Recent news around DuPont has focused on the company's portfolio positioning and its place in the broader...

Domino’s Pizza (DPZ) has wrapped up FY 2025 with fourth quarter revenue of US$1.5b and basic EPS of US$5.35, setting the tone for a year where trailing twelve month revenue came in at about US$4.9b and EPS reached US$17.69. Over recent quarters, revenue has ranged from US$1.1b to US$1.5b while quarterly EPS has moved between roughly US$3.84 and US$5.35. This gives investors a clear read on how sales and earnings are tracking into the current share price of US$414.20. With trailing net margins...

In February 2026, Lazard, Inc. added John Koski and Rob Lowe as Managing Directors in its New York Healthcare Group, bringing experience across payors, providers, distributors, and healthcare–technology transactions from roles at Allen & Co. and Citi. Around the same time, Lazard reported quarterly results with revenue growth but pressure on margins and earnings, prompting investors to weigh expansion efforts against profitability trends and insider share sales. Next, we’ll examine how...

If you are wondering whether PACCAR's current share price reflects its underlying worth, this article walks through the key numbers that matter for valuation. PACCAR's stock recently closed at US$126.25, with returns of 3.5% over the past 30 days, 13.2% year to date, and 21.5% over the last year. The 7 day return sits at a 0.2% decline and the 3 year and 5 year returns are 95.3% and 142.0% respectively. Recent news around PACCAR has focused on its position as a major commercial vehicle...

Park Hotels & Resorts (PK) shares are back in focus after the company reported fourth quarter and full year 2025 results, paired with fresh 2026 guidance, a leadership change, and a reaffirmed cash dividend. See our latest analysis for Park Hotels & Resorts. The latest results, dividend affirmation and the appointment of Sean Dell’Orto as COO come as Park Hotels & Resorts trades near US$11.27, with a 90 day share price return of 4.06% and a 3 year total shareholder return of 13.70%. This...

Keurig Dr Pepper (KDP) has wrapped up FY 2025 with fourth quarter revenue of US$4.5 billion and basic EPS of US$0.26, setting the tone for how investors assess the full year. The company has seen quarterly revenue move from US$4.1 billion in Q4 2024 to US$4.5 billion in Q4 2025, while quarterly EPS shifted from a loss of US$0.11 to EPS of US$0.26 over the same period, against a trailing twelve month EPS of US$1.53. With trailing net margin at 12.5% and earnings growth highlighted over the...

Investors may be wondering if Box is starting to look like a value opportunity after a rough patch, or if the market is rightly cautious about the stock at around US$22.82. The share price has been under pressure, with a 0.6% move over the last week, a 13.8% decline over 30 days, a 20.8% decline year to date, and a 31.1% decline over the past year. However, the 5 year return sits at 21.7%. Recent coverage around Box has focused on its position as a listed software player and how investors...

In February 2026, Gentherm reported fourth‑quarter 2025 earnings showing net income falling to US$2.99 million from US$15.32 million a year earlier, while quarterly revenue of about US$382.79 million came in ahead of expectations. Alongside weaker profitability, Gentherm issued product revenue guidance of US$1.5 billion to US$1.6 billion for 2026 and US$1.7 billion for 2027, highlighting its ambition to grow beyond automotive into medical and other precision thermal applications. We’ll now...

DigitalOcean Holdings FY 2025 Earnings Snapshot DigitalOcean Holdings (DOCN) has wrapped up FY 2025 with Q4 revenue of US$242.4 million and basic EPS of US$0.28, capping off a year in which trailing twelve month revenue reached US$901.4 million and EPS came in at US$2.83. The company has seen revenue move from US$780.6 million to US$901.4 million on a trailing twelve month basis, while EPS shifted from US$0.92 to US$2.83, with reported earnings growth helped by a very large year over year...

If you are wondering whether Bruker is priced attractively right now, you are not alone, especially with sentiment around the stock shifting recently. The share price closed at US$39.77, with a 4.3% gain over the last 7 days, set against returns of a 21.0% decline over 30 days, a 17.3% decline year to date, and a 21.6% decline over 1 year, as well as 41.7% and 35.1% declines over 3 and 5 years respectively. These mixed shorter term and longer term returns have put more attention on what...

If you are wondering whether TG Therapeutics at around US$30.51 is priced attractively or already baking in a lot of optimism, you are in the right place. The stock has returned 5.0% over the last 7 days, is down 2.2% over 30 days, and shows mixed longer term results with a 4.2% return year to date, 4.5% over 1 year, 90.4% over 3 years, and a 32.0% decline over 5 years. These moves sit against a backdrop of ongoing interest in TG Therapeutics as a biotechnology name, with investors watching...

Twist Bioscience, NasdaqGS:TWST, has entered a co exclusive licensing agreement with Invenra Inc. for Invenra's B Body bispecific antibody platform. The deal expands Twist's antibody discovery services and includes an equity investment and licensing terms that share economics between the two companies. This move adds bispecific antibody capabilities to Twist's existing biologics discovery tools, broadening the range of programs it can support for biotech and pharma customers. Twist...

If you are trying to work out whether Caris Life Sciences at around US$18.20 is a bargain or a value trap, you are in the right place. The stock has been under pressure recently, with a 12.5% decline over the last 7 days, a 27.2% decline over the last 30 days, and a 32.5% decline year to date. Recent attention around Caris Life Sciences has focused on its position in the pharmaceuticals and biotech space and how investors are reassessing risk in the sector. This backdrop helps explain why...

If you are wondering whether Danaos is still good value after its recent run, you are in the right place. This article focuses squarely on what you are paying for each dollar of the business. The stock last closed at US$111.57, with returns of 4.0% over 7 days, 10.8% over 30 days, 17.1% year to date, 41.5% over 1 year and 116.4% over 3 years. These figures naturally raise questions about how much upside or risk is now priced in. Recent coverage of Danaos has highlighted its role in the...

If you are wondering whether Inspire Medical Systems' share price now reflects good value or lingering risk, you are not alone. The stock last closed at US$57.72, with returns of 4.4% decline over 7 days, 27.3% decline over 30 days, 37.4% decline year to date, 68.8% decline over 1 year, 77.8% decline over 3 years and 76.1% decline over 5 years. Recent coverage has focused on how the share price pullback has reshaped expectations around the company and the sleep apnea treatment market it...

Concentra Group Holdings Parent: Recent Moves In Context With no single headline event driving attention to Concentra Group Holdings Parent (CON), investors are focusing on how its recent share performance and financial profile fit into the occupational health services story. See our latest analysis for Concentra Group Holdings Parent. At a share price of $23.41, Concentra Group Holdings Parent has paired a 1 month share price return of 8.63% with a year to date share price return of 20.61%...

In February 2026, Neurocrine Biosciences reported that fourth-quarter 2025 revenue rose to US$805.5 million and net income to US$153.7 million, with full-year revenue reaching US$2.86 billion and net income US$478.6 million, alongside higher basic and diluted earnings per share from continuing operations versus 2024. The company also issued 2026 guidance calling for INGREZZA net product sales of US$2.70 billion to US$2.80 billion, underscoring the central role of this flagship therapy in...

If you are wondering whether Regal Rexnord’s current share price really reflects what the business is worth, you are not alone. This article is built to help you assess that question clearly. With the stock at US$223.69 and returns of 2.1% over 7 days, 43.3% over 30 days, 53.1% year to date and 69.7% over 1 year, many investors are asking what is already priced in and what might still be on the table in terms of risk and reward. These moves sit against a backdrop where Regal Rexnord...

If you are wondering whether Knowles is fairly priced at around US$28.07 per share, you are not alone. This article will focus squarely on what that means for value minded investors. The stock has posted returns of 3.4% over the past week, 17.3% over the last 30 days, 27.9% year to date, 62.5% over 1 year and 65.3% over 3 years, with a 5 year return of 32.8%. This naturally raises questions about what is already reflected in the price. Recent coverage around Knowles has centered on its...

What the latest earnings and guidance mean for 10x Genomics (TXG) 10x Genomics (TXG) just paired its fourth quarter and full year 2025 results with new 2026 revenue guidance. This gives investors fresh data on growth, profitability and how management is framing the year ahead. See our latest analysis for 10x Genomics. 10x Genomics shares are at US$19.10, with a 1 day share price return of 1.11% and a 7 day share price return of 2.58%. The 30 day share price return shows a 14.66% decline,...

If you are wondering whether Dominion Energy's current share price offers real value or only appears reassuring at first glance, this article will help you make sense of where it stands. The stock last closed at US$63.74, with a 2.9% pullback over the past week, a 6.9% gain over 30 days, and returns of 7.6% year to date, 16.3% over 1 year, 33.1% over 3 years and 13.8% over 5 years. Recent coverage of Dominion Energy has focused on its position as a large regulated utility and on how...